Opinion|Videos|June 26, 2024
Efficacy and Safety Trials Results of Complement Inhibitors
Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Several complement inhibitors have been approved since eculizumab, including ravulizumab, a long-acting C5 inhibitor; danicopan, a factor D inhibitor; pegcetacoplan, a complement C3 inhibitor; and iptacopan, a complement factor B inhibitor. Please discuss the efficacy and safety results from the pivotal trials for each of these treatments.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success
2
Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups
3
High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial
4
AHA Proposes Staging System for Pediatric Cardiogenic Shock
5